MK-0482 / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MK-0482 / Merck (MSD)
KEYMAKER-U01C, NCT04165096 / 2020-001629-29: KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/)

Active, not recruiting
2
135
Europe, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, Boserolimab, MK-5890, MK-4830, diphenhydramine, acetaminophen, MK-0482
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
02/32
02/32
KEYMAKER-U01B, NCT04165083 / 2020-001627-14: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/)

Active, not recruiting
2
120
Europe, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, SCH 900475, MK-4830, MK-0482
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
09/25
09/25
KEYMAKER-U01A, NCT04165070 / 2020-001626-56: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/)

Hourglass Jan 2022 - Dec 2022 : Of KEYNOTE-01A trial for advanced NSCLC
Active, not recruiting
1/2
450
Europe, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, PARAPLATIN®, Paclitaxel, ABRAXANE®, Pemetrexed, ALIMTA®, Vibostolimab, MK-7684, Boserolimab, MK-5890, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400, HER3-DXd, U3-1402, MK-1022
Merck Sharp & Dohme LLC, Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
02/39
02/39
NCT06413095: PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Completed
1
13
US
Pembrolizumab, Keytruda, MK-3475, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Presage Biosciences, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
06/23
06/23
MK-0482-001, NCT03918278: A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors

Active, not recruiting
1
230
Europe, Canada, US, RoW
MK-0482, pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Carboplatin, Paraplatin ®, Pemetrexed, Alimta
Merck Sharp & Dohme LLC
Neoplasms
02/25
02/25
MK-0482-002, NCT05038800: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Terminated
1
12
Europe, US, RoW
MK-0482
Merck Sharp & Dohme LLC
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
12/23
12/23
NCT04541108: Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting
1
15
US
Rilvegostomig, AZD2936, Volrustomig, MEDI5752, Sabestomig, AZD7789, Pembrolizumab, Keytruda, MK-3475
Presage Biosciences, Merck Sharp & Dohme LLC
Solid Tumor
12/31
12/31

Download Options